Table 3.
Competing Risk Analysis
| Unaffected N (%) | Breast cancer N (%) | Ovarian cancer N (%) | Breast cancer
|
Ovarian cancer
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% C.I. | P-value | HR | 95% C.I. | P-value | |||||
| 8q24—rs10088218 | ||||||||||
| BRCA1 | GG | 3,661 (77.0) | 4,772 (75.5) | 1,119 (76.4) | 1 | 1 | ||||
| AG | 1,025 (21.5) | 1,431 (22.6) | 330 (22.5) | 1.03 | 0.94–1.11 | 0.96 | 0.83–1.11 | |||
| AA | 70 (1.5) | 117 (1.9) | 16 (1.1) | 1.08 | 0.84–1.38 | 0.55 | 0.32–0.94 | |||
| 2-df test | 0.72 | 0.083 | ||||||||
| per allele | 1.03 | 0.96–1.10 | 0.44 | 0.91 | 0.80–1.03 | 0.13 | ||||
| BRCA2 | GG | 2,123 (73.9) | 2,861 (75.3) | 366 (80.6) | 1 | 1 | ||||
| AG | 699 (24.3) | 877 (23.1) | 77 (17.0) | 0.91 | 0.82–1.02 | 0.60 | 0.46–0.78 | |||
| AA | 53 (1.8) | 62 (1.6) | 11 (2.4) | 0.85 | 0.61–1.18 | 1.17 | 0.60–2.27 | |||
| 2-df test | 0.17 | 7.7 × 10−4 | ||||||||
| per allele | 0.92 | 0.84–1.00 | 0.061 | 0.72 | 0.57–0.91 | 5.7 × 10−3 | ||||
| 3q25–rs2665390 | ||||||||||
| BRCA1 | TT | 3,716 (85.2) | 4,995 (85.7) | 1,151 (82.8) | 1 | 1 | ||||
| TC | 614 (14.1) | 801 (13.7) | 229 (16.4) | 1.00 | 0.90–1.11 | 1.27 | 1.06–1.51 | |||
| CC | 31 (0.7) | 33 (0.6) | 11 (0.8) | 0.80 | 0.53–1.19 | 1.22 | 0.62–2.41 | |||
| 2-df test | 0.54 | 0.028 | ||||||||
| per allele | 0.98 | 0.89–1.08 | 0.70 | 1.23 | 1.06–1.44 | 8.5 × 10−3 | ||||
| BRCA2 | TT | 2,282 (85.5) | 3,067 (85.1) | 326 (76.8) | 1 | 1 | ||||
| TC | 368 (13.8) | 517 (14.4) | 95 (22.5) | 1.02 | 0.89–1.16 | 1.75 | 1.34–2.27 | |||
| CC | 19 (0.7) | 20 (0.6) | 3 (0.7) | 0.72 | 0.39–1.35 | 1.02 | 0.21–5.10 | |||
| 2-df test | 0.57 | 1.6 × 10−4 | ||||||||
| per allele | 0.99 | 0.87–1.12 | 0.82 | 1.59 | 1.25–2.02 | 1.9 × 10−4 | ||||
| 2q31–rs717852 | ||||||||||
| BRCA1 | TT | 1,817 (47.3) | 2,576 (46.5) | 606 (45.5) | 1 | 1 | ||||
| CT | 1,667 (43.5) | 2,400 (43.3) | 602 (45.1) | 1.01 | 0.94–1.09 | 1.10 | 0.96–1.25 | |||
| CC | 356 (9.3) | 562 (10.2) | 125 (9.4) | 1.13 | 0.99–1.29 | 1.10 | 0.87–1.40 | |||
| 2-df test | 0.18 | 0.32 | ||||||||
| per allele | 1.04 | 0.99–1.10 | 0.14 | 1.08 | 0.98–1.19 | 0.15 | ||||
| BRCA2 | TT | 1,345 (49.8) | 1,752 (47.5) | 177 (41.4) | 1 | 1 | ||||
| CT | 1,112 (41.2) | 1,603 (43.5) | 202 (47.2) | 1.08 | 0.98–1.19 | 1.39 | 1.11–1.74 | |||
| CC | 244 (9.0) | 331 (9.0) | 50 (11.5) | 1.03 | 0.87–1.21 | 1.60 | 1.13–2.26 | |||
| 2-df test | 0.30 | 3.8 × 10−3 | ||||||||
| per allele | 1.04 | 0.97–1.12 | 0.30 | 1.31 | 1.12–1.53 | 8.5 × 10−4 | ||||
| 17q21–rs9303542 | ||||||||||
| BRCA1 | TT | 2,537 (53.1) | 3,470 (54.8) | 764 (52.3) | 1 | 1 | ||||
| TC | 1,891 (39.6) | 2,434 (38.5) | 586 (40.1) | 0.98 | 0.91–1.05 | 1.08 | 0.95–1.23 | |||
| CC | 349 (7.3) | 426 (6.7) | 111 (7.6) | 0.95 | 0.82–1.09 | 1.10 | 0.87–1.40 | |||
| 2-df test | 0.70 | 0.44 | ||||||||
| per allele | 0.98 | 0.92–1.03 | 0.41 | 1.06 | 0.97–1.17 | 0.22 | ||||
| BRCA2 | TT | 1,517 (52.8) | 2,012 (53.1) | 212 (46.7) | 1 | 1 | ||||
| TC | 1,136 (39.6) | 1,520 (40.1) | 203 (44.9) | 0.98 | 0.89–1.08 | 1.26 | 1.02–1.55 | |||
| CC | 218 (7.6) | 259 (6.8) | 38 (8.4) | 0.87 | 0.73–1.05 | 1.17 | 0.79–1.74 | |||
| 2-df test | 0.35 | 0.099 | ||||||||
| per allele | 0.96 | 0.89–1.03 | 0.22 | 1.16 | 0.99–1.35 | 0.075 | ||||
Associations with breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Analysis restricted to mutation carriers of European ancestry.